Formulation, characterization, and evaluation of ligand-conjugated biodegradable quercetin nanoparticles for active targeting
Source abstract
Abstract
The aim of this study was to design a targeted drug delivery system carrying a natural anticancer drug Quercetin (Qu), specifically for skin cancer. A central composite design was applied separately for each ligand, and the quadratic model was used for the process. The surface morphology was confirmed by transmission electron microscopy (TEM) and Fourier transform infrared spectroscopy (FTIR), and in vitro release studies were also performed. The MTT assay was performed against two different cell lines, to measure their anticancer potentials and their targeting ability. The study thus reveals that MA-Qu-PLGA and FA-Qu-PLGA nanoparticles (NPs) can be used as effective drug delivery systems for skin cancer treatment encompassing natural drugs.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advancements in Transdermal Drug Delivery · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (37)
Show source-provided references
1. 10.1016/S0168-3659(00)00339-410.1016/S0168-3659(00)00339-4 ↗
2. 10.3390/polym303137710.3390/polym3031377 ↗
3. 10.1016/j.addr.2007.04.01210.1016/j.addr.2007.04.012 ↗
4. 10.1016/S0378-5173(02)00220-X10.1016/S0378-5173(02)00220-X ↗
5. 10.1016/j.addr.2007.04.00610.1016/j.addr.2007.04.006 ↗
6. Uner M · Pharmazie · 2006 · 61 · 375
7. 10.1016/j.colsurfa.2007.08.00510.1016/j.colsurfa.2007.08.005 ↗
8. Lin X · Colloids Surf A Physicochem Eng Asp · 2007 · 311 · 10610.1016/j.colsurfa.2007.06.003 ↗
9. Lee JW · Bioorg Med Chem · 2002 · 10 · 239710.1016/S0968-0896(02)00019-6 ↗
10. 10.1517/14712598.8.8.106310.1517/14712598.8.8.1063 ↗
11. Mittal V · Intern. J Pharma Bio Sci · 2010 · 1 · 1
12. 10.1002/1520-6017(200011)89:11<1452::AID-JPS8>3.0.CO;2-P10.1002/1520-6017(200011)89:11<1452::AID-JPS8>3.0.CO;2-P ↗
13. 10.1088/0957-4484/21/28/28510710.1088/0957-4484/21/28/285107 ↗
14. 10.1016/j.ejpb.2004.04.00610.1016/j.ejpb.2004.04.006 ↗
15. 10.1016/j.biomaterials.2011.04.00610.1016/j.biomaterials.2011.04.006 ↗
16. Lu Y · J Liposome Res · 2012 · 22 · 11010.3109/08982104.2011.627514 ↗
17. Zhang L · Int J Nanomed · 2012 · 7 · 151
18. Dosio F · Curr Opin Investig Drugs · 2010 · 11 · 1424
19. Xia Q · Colloids Surf A: Physicochem Eng Asp · 2008 · 313 · 2710.1016/j.colsurfa.2007.04.067 ↗
20. 10.1111/j.1750-3841.2007.00641.x10.1111/j.1750-3841.2007.00641.x ↗
21. Wu G · J Nanomater · 2012 · 2012 · 1
22. 10.1016/j.ijpharm.2007.03.02210.1016/j.ijpharm.2007.03.022 ↗
23. 10.1016/S0169-409X(01)00105-310.1016/S0169-409X(01)00105-3 ↗
24. 10.1021/js950353+10.1021/js950353+ ↗
25. 10.1016/j.seppur.2007.09.00510.1016/j.seppur.2007.09.005 ↗
26. 10.1016/j.ejpb.2004.03.03710.1016/j.ejpb.2004.03.037 ↗
27. 10.1016/j.foodchem.2007.07.06710.1016/j.foodchem.2007.07.067 ↗
28. 10.1016/j.powtec.2009.09.00410.1016/j.powtec.2009.09.004 ↗
29. Liu CH · Colloids Surf A Physicochem Eng Aspects · 2010 · 353 · 14910.1016/j.colsurfa.2009.11.006 ↗
30. Gambhire M · Current Pharma Res · 2011 · 1 · 15710.33786/JCPR.2011.v01i02.012 ↗
31. Ghasemian E · DARU J Pharm Sci · 2013 · 21 · 6810.1186/2008-2231-21-68 ↗
32. Chidambaram M · J Pharm Pharm Sci · 2011 · 14 · 6710.18433/J30C7D ↗
33. 10.1111/j.2042-7158.2012.01486.x10.1111/j.2042-7158.2012.01486.x ↗
34. Cooper DL · PLoS ONE · 2014 · 9 · e8732610.1371/journal.pone.0087326 ↗
35. Yadav KS · AAPS Pharm Sci Tech · 2010 · 11 · 145610.1208/s12249-010-9519-4 ↗
36. 10.1016/S0378-5173(02)00076-510.1016/S0378-5173(02)00076-5 ↗
37. Varshosaz J · J Liposome Res · 2013 · 22